7936:TSEAsics Corporation Analysis
Data as of 2026-05-18 - not real-time
¥4,436.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
ASICS trades at ¥4,436, comfortably above its 20‑day SMA of ¥4,565 and the 50‑day SMA of ¥4,466, indicating a short‑term pull‑back. The 30‑day volatility of 45.6% and a computed beta of 0.43 suggest the stock can swing sharply while remaining less correlated with the broader market. RSI sits at 46.7, just below neutral, and the MACD histogram is negative with a bearish signal line, reinforcing downside pressure. Volume is increasing, providing liquidity, but price is nearing the technical support at ¥4,271. The overall technical picture is mixed, leaning toward caution in the near term.
On the fundamentals side, revenue surged 29.7% YoY to ¥872.9 bn, with a robust gross margin of 56% and an operating margin of 22%, underscoring strong pricing power. ROE stands at an impressive 40.9% and free cash flow is ¥38.2 bn, supporting a low 20% payout ratio and a sustainable dividend yield of 0.86%. However, the market price is more than double the discounted cash‑flow fair value of ¥1,891, and the PE of 32× and PB of 11.5× signal that the stock is heavily overvalued. Analyst consensus remains “Buy” with a median target of ¥5,450, implying roughly a 20% upside from current levels, but this relies on continued growth momentum. The “Extreme Greed” sentiment index (89.6) further highlights potential over‑enthusiasm. In summary, while the growth engine is solid, valuation compression and technical weakness temper enthusiasm. Investors should weigh the overvaluation against the company’s strong fundamentals before deciding on entry timing.
On the fundamentals side, revenue surged 29.7% YoY to ¥872.9 bn, with a robust gross margin of 56% and an operating margin of 22%, underscoring strong pricing power. ROE stands at an impressive 40.9% and free cash flow is ¥38.2 bn, supporting a low 20% payout ratio and a sustainable dividend yield of 0.86%. However, the market price is more than double the discounted cash‑flow fair value of ¥1,891, and the PE of 32× and PB of 11.5× signal that the stock is heavily overvalued. Analyst consensus remains “Buy” with a median target of ¥5,450, implying roughly a 20% upside from current levels, but this relies on continued growth momentum. The “Extreme Greed” sentiment index (89.6) further highlights potential over‑enthusiasm. In summary, while the growth engine is solid, valuation compression and technical weakness temper enthusiasm. Investors should weigh the overvaluation against the company’s strong fundamentals before deciding on entry timing.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD and RSI below 50
- Price below short‑term SMAs
- High 30‑day volatility
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth and margins
- Low payout ratio supporting dividend sustainability
- Analyst median target indicating ~20% upside
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Current price more than double DCF fair value
- High valuation multiples (PE, PB)
- Robust brand and cash‑flow generation
Key Metrics & Analysis
Financial Health
Revenue Growth29.70%
Profit Margin13.02%
P/E Ratio32.2
ROE40.86%
ROA17.20%
Debt/Equity42.27
P/B Ratio11.6
Op. Cash Flow¥95.3B
Free Cash Flow¥38.2B
Technical Analysis
TrendBullish
RSI46.7
Support¥4,271.00
Resistance¥5,149.00
MA 20¥4,565.25
MA 50¥4,465.62
MA 200¥4,058.73
MACDBearish
VolumeIncreasing
Fear & Greed Index89.61
Valuation
Fair Value¥1,891.53
Target Price¥5,332.86
Upside/Downside20.22%
GradeOvervalued
TypeGrowth
Dividend Yield0.86%
Risk Assessment
Beta0.43
Volatility45.63%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.